Skip to content.

Bloomsbury GTX raises £5m Seed funding to develop curative gene therapy treatments


Life Sciences UCL Tech Fund


Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases, based on clinically proven gene therapy technologies, today announced its launch with £5 million Seed financing led by UCL Technology Fund.

Bloomsbury’s innovative approach is built on a proven gene therapy platform and is designed to optimise therapeutic efficacy and safety, enable high manufacturability, accelerate development timelines and maximise regulatory success to create a pipeline of highly differentiated first- or best-in-class programs.

“Bloomsbury is developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases,” “Our approach has been designed with a single goal in mind – to deliver the promise of gene therapy to rare disease patients by leveraging our industry’s existing state-of-the art technology and we have already attracted a highly talented team of founders and experienced scientific and business professionals to the Company to that effect as we progress our first liver targeted gene therapy program, BGT-OTCD for the treatment of Ornithine Transcarbamylase Deficiency, into the clinic.”

Adrien Lemoine, Co-Founder & Chief Executive Officer of Bloomsbury.

“Our commitment to Bloomsbury is a great example of our strategy to seek to build truly innovative companies anchored by exceptional science and experienced teams. We are excited by the potential to develop best-in-class products in the gene therapy space.”


Bloomsbury was founded as a spinout from UCL and is underpinned by world-leading gene therapy and rare disease expertise academic founders.

Bloomsbury is led by Co-Founder & Chief Executive Officer, Adrien Lemoine, who brings 20 years of experience in pharma and biotech, including senior commercial, strategy and operation roles at AstraZeneca and GSK.

Read more here: Bloomsbury Genetic Therapies (